New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 18, 2012
08:08 EDTTRIBTrinity Biotech reports Q3 ADR 19.8c, consensus 20c
Reports Q3 revenue $20.9M, consensus $.21.96M
News For TRIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
11:28 EDTTRIBTrinity Biotech announces CLIA waiver of rapid syphilis test
Subscribe for More Information
09:58 EDTTRIBTrinity Biotech's CLIA waiver an unexpected positive, says Craig-Hallum
The FDA granted the first-ever CLIA waiver for a point of care Syphilis test. Craig-Hallum said Trinity has the exclusive right to sell in the U.S. market, which could add $3M-$5M in 2015 revenues, and $10M-$15M longer term. Shares are Buy rated.
December 15, 2014
12:17 EDTTRIBSyphilis test distributed by Trinity gets CLIA waiver from FDA
The FDA announced that it granted the first-ever waiver, under certain laboratory regulations, for a rapid screening test for syphilis, which will allow the Syphilis Health Check test to be used in a greater variety of health care settings. The FDA's waiver is related to the Clinical Laboratory Improvement Amendments, federal standards that apply to clinical laboratory testing on humans, with certain exceptions. Because the FDA granted a waiver under CLIA, the Syphilis Health Check test can be distributed to a variety of nontraditional laboratory sites, including physicians' offices and emergency rooms. The waiver also allows untrained health care workers to perform the tests on patients. The Syphilis Health Check test is manufactured by VEDA LAB of France for Diagnostics Direct. It is also distributed by Trinity Biotech (TRIB).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use